-
Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy
-
Sebastia Sabater, Meritxell Arenas, Roberto Berenguer, Ignacio Andres, Esther Jimenez-Jimenez, Ana Martos, Jesus Fernandez-Lopez, Mar Sevillano, Angeles Rovirosa
-
Cancer Res Treat. 2015;47(3):473-479. Published online November 24, 2014
-
DOI: https://doi.org/10.4143/crt.2014.115
-
-
 Abstract
 PDF PubReader ePub
- Purpose
Association between body mass index (BMI) and doses in organs at risk during postoperative vaginal cuff brachytherapy (VCB) treatment has not been evaluated. The aim of this study was to analyse the impact of BMI on the dose delivered to bladder and rectum during high-dose-rate VCB using computed tomography (CT) scans at every fraction.
Materials and Methods
A retrospective analysis of 220 planning CT sets derived from 59 patients was conducted.
Every planning CT was re-segmented and re-planned under the same parameters. Rectum and bladder dose-volume histogram values (D0.1cc, D1cc, and D2cc) were extracted and evaluated. The mean values for all applications per patient were calculated and correlated with BMI, as well as other factors influencing rectal and bladder doses. Multiple regression analysis performed to model organ at risk dose-volume parameters.
Results
According to World Health Organization (WHO), 6.8% of patients were normal, 35.6% were
overweight, and 57.6% were class I obese. Median rectal doses were 133.5%, 110.9%, and 99.3% for D0.1cc, D1cc, and D2cc, respectively. The corresponding median bladder doses were 96.2%, 80.6%, and 73.3%, respectively. BMI did not show significant association with rectal doses. However, BMI did show a significant association with evaluated bladder dose metrics (D0.1cc, r=–0.366, p=0.004; D1cc, r=–0.454, p < 0.001; D2cc, r=–0.451, p < 0.001). BMI was retained in the multivariate regression models (D0.1cc, p=0.004; D1cc, p < 0.001; D2cc, p=0.001).
Conclusion
In this group of Mediterranean, overweight, and moderately obese patients, BMI showed
association with lower bladder dose values, but not with rectal doses.
-
Citations
Citations to this article as recorded by  - Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
Yaowen Zhang, Faegheh Noorian, Rosa Abellana, José Rochera, Antonio Herreros, Gabriela Antelo, Valentina Lancellotta, Luca Tagliaferri, Qian Han, Aureli Torne, Angeles Rovirosa
Clinical and Translational Oncology.2023; 25(6): 1748. CrossRef - Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy
Chris Osam Doudoo, Prince Kwabena Gyekye, Geoffrey Emi-Reynolds, Simon Adu, David Okoh Kpeglo, Samuel Nii Adu Tagoe, Kofi Agyiri
Journal of Medical Imaging and Radiation Sciences.2023; 54(2): 335. CrossRef - Influence of body habitus on dose parameters of nodal levels III to IV irradiation for breast cancer: comparison of 3 techniques
Sebastia Sabater, Marina Gascon, Manuel Gutierrez-Perez, Roberto Berenguer, Ellen M. Donovan, Emma J. Harris, Meritxell Arenas
Medical Dosimetry.2018; 43(4): 328. CrossRef - Does postoperative irradiation improve survival in early-stage endometrial cancer?
Sebastia Sabater, Ignacio Andres, Veronica Lopez-Honrubia, Maria Magdalena Marti-Laosa, Susana Castro-Larefors, Roberto Berenguer, Esther Jimenez-Jimenez, Marimar Sevillano, Angeles Rovirosa, Meritxell Arenas
Brachytherapy.2018; 17(6): 912. CrossRef - Body mass index and outcomes of endometrial and ovarian cancer patients
Anke Smits, Alberto Lopes, Ruud Bekkers, Leon Massuger, Khadra Galaal
Expert Review of Quality of Life in Cancer Care.2016; 1(3): 221. CrossRef
-
15,861
View
-
60
Download
-
8
Web of Science
-
5
Crossref
|
KCA
